Blog
ICER Released First Cost-Effectiveness Assessment for a Digital Therapeutic (DTx)
Published November 3, 2020
Written by Tom Rutkowski and Patrick Buck…
Home / Intelligence
Webinars
Unlock the Potential of Generative AI in Life Sciences Insights and Operations
May 2, 2024 | 1:00 - 1:45 PM ET
Generative AI (GenAI) has created an opportunity to re-think and significantly improve how we work. GenAI has the potential to make pharma professionals far more effective and valuable to their organizations. Join us for “Making AI Real,” a webinar series dedicated to exploring how to leverage generative AI across different areas within pharmaceutical commercial operations and medical affairs.
Recommended
White Papers
Picking Winners: Portfolio Management for a New Era
White Papers
Evidence Generation in a Post-IRA World
Webinars
RWE + PMR: A Powerful Approach to Demand Forecasting, Segmentation and MoreMay 14, 2024 | 1:00 - 1:45 PM ET
Webinars
COVID-19 Impact on Launch Performance
Available On Demand
How has COVID-19 impacted launch performance and timing? Pharmaceutical leaders are facing some of the toughest challenges of their careers when it comes to launching in the midst of COVID-19. With so much at stake and so much uncertainty, companies are looking for fact-based insights to power their decision-making. Trinity has done an in-depth evaluation of the impact of COVID-19 on launch performance and timing. We have compared forecasted/expected revenue to actual revenue for products that launched within six months…
Webinars
COVID-19 Forecasting: Seeking Clarity in a World of Uncertainty
Available On Demand
Forecasters in the life sciences industry are facing novel challenges in the midst of the COVID-19 pandemic. With so much at stake, and so much change, forecasting in this environment is both vital and difficult. Companies are looking for the best ways to model scenarios for the future of COVID-19 and incorporate those decisions into their forecasting and decision-making. Key Takeaways Insights into assumptions that are critical to projecting the future of the COVID-19 pandemic. Examples of how different scenarios…
Blog
FDA Launches the Digital Health Center of Excellence
Published October 15, 2020
Written by Tom Rutkowski, Jay Galli, and Kate Watkins…
Blog
CAR-Ts: Barriers and Opportunities for the Migration into Earlier Lines of Therapy in the USA
Published September 22, 2020
Executive Summary Although CAR-Ts are on the cutting edge of oncology treatment, they are still only approved for administration following at least two other lines of treatment Key barriers for CAR-T migration into earlier lines include the complex logistics and site of care restrictions, a lack of comparative 3L+ and 2L clinical trial data, and reimbursement uncertainty in fee-for-service (FFS) Medicare New opportunities to overcome these hurdles are being pursued in the form of innovative pricing and contracting strategies to…
Case Studies
Early Payer Guidance Across Four Inflammatory Disease Areas
Trinity completed an early payer guidance engagement, conducting comprehensive secondary research across four inflammatory disease areas. Geographic Scope: Client Situation The client wanted to gain an in-depth understanding of four inflammatory disease areas to inform early stage decision-making. Trinity’s Solution Trinity conducted comprehensive secondary research in the following areas: Disease background including diagnosis, prognosis, epidemiology and unmet needsCurrent and future paradigm including lines of therapies and standard of carePipeline analysis including key therapies in development and future treatment gamechangersPricing and access landscape including pricing analysis, health…
Blog
Ten Long-Term Impacts of COVID-19 on Biopharma
Published August 25, 2020
Written by Michaela Broadhurst, Olivia Gugliemini, Emily Lewis, and Tom Rutkowski…
Case Studies
P&MA Assessment to Support BD&L Decision-Making
Trinity completed a P&MA assessment for a gene therapy in Leber hereditary optic neuropathy (LHON) to support BD&L decision-making. Geographic Scope: Client Situation The client wanted to understand the current and future market landscape and the resulting pricing and access potential for a gene therapy asset in Leber hereditary optic neuropathy to support their BD&L decision-making. Trinity’s Solution Trinity conducted in-depth interview (IDI) discussions with payers and key opinion leaders (KOLs) to evaluate current treatment practices and price thresholds for LHON, and understand likely payer restrictions as a function of price.…
Case Studies
Cross-Functional Launch Strategy Alignment Workshop
Trinity organized a full day on-site workshop to bring together key cross functional client teams to align on a final launch strategy for their mNSCLC asset in Japan. Geographic Scope: Client Situation: The client wanted to build alignment on the launch pricing & market access assumptions for their asset in metastatic non-small cell lung cancer (mNSCLC) and metastatic colorectal cancer (mCRC) in Japan, including consideration of all forecasting assumptions and pricing and market access (P&MA) risks. Trinity’s Solution: Trinity conducted targeted secondary research to determine the existing mNSCLC…
Case Studies
Biosimilar Differentiation Strategy
Trinity developed a strategy to drive differentiation of a biosimilar through service offerings and contracting in Canada, and select LatAm and MEA countries. Geographic Scope: Client Situation: The client wanted to identify the service offerings and contracting that can drive differentiation and preference of a biosimilar versus the originator biologic and other biosimilars. Trinity’s Solution Trinity conducted an internal working session with the local and regional team to vet hypotheses, followed by a semi-qual / quant primary research program moderated in local language with n=185 stakeholders, including key opinion leaders (KOLs), physicians, nurses,…
Sign up for the latest intelligence
By signing up, you are agreeing to our Privacy Policy.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.